News Release

New York Valves™ 2025 late-breaking clinical trials announced

CRF’s premier structural heart summit returns to NYC June 25-27

Meeting Announcement

Cardiovascular Research Foundation

NEW YORK – June 16, 2025 – The Cardiovascular Research Foundation® (CRF®) announced the lineup of Late-Breaking Clinical Trials to be presented at New York Valves: The Structural Heart Summit taking place June 25-27, 2025, at the Jacob K. Javits Convention Center, North in New York, NY.

This year’s program will spotlight 12 late-breaking trials, showcasing the latest advances, key trial results, and innovative therapies transforming the field of structural heart disease. Formerly known as the Transcatheter Valve Therapy (TVT®) conference and now in its second year, New York Valves 2025 continues to evolve as the must-attend educational meeting for interventionalists, imagers, surgeons, and the entire heart team.

The late-breaking clinical research that will be presented at New York Valves will unveil the latest advances in transcatheter aortic valve replacement, alongside innovations in mitral and tricuspid devices and techniques. Data from these trials will help guide the selection of patients who will benefit most from these procedures and help define optimal treatment strategies, tools, and techniques for new and emerging treatments.

Wednesday, June 25, 2025

Late-Breaking Clinical Trials 1: Aortic

10:30 AM — 11:30 AM EDT

Guideline Directed Indications and Consequences of Delayed AVR in Patients With Asymptomatic, Severe Aortic Stenosis: Results From the EARLY TAVR Trial

Allan Schwartz

Electronic Provider Notification Mitigates Sex Disparities in the Treatment of Severe Aortic Stenosis: Insights From the DETECT AS Trial

Sammy Elmariah

TAVR Reintervention Strategies: Unveiling Trends and Outcomes of Redo TAVR and TAVR Explant

Shinichi Fukuhara

Early US Commercial Experience With a Self-Expandable Transcatheter Aortic Valve With Intra-Annular Leaflet Position

Santiago Garcia

Thursday, June 26, 2025

Late Breaking Clinical Trials 2: Tricuspid

10:30 AM — 11:30 AM EDT

Clinical Progression in TRILUMINATE Pivotal Control Group: Insights Into Crossover to Tricuspid TEER

Matthew J. Price

TRISCEND II: Echocardiographic Outcomes One Year Post Transcatheter Tricuspid Valve Replacement

Paul A. Grayburn

Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

Suzanne V. Arnold

Prognostic Impact of Extra-Tricuspid Valve Involvement After Tricuspid Transcatheter Edge-to-Edge Repair: Insights from the Bronx Valve and TRISPA Registries

Julio Echarte Morales

Friday, June 27, 2025

Late Breaking Clinical Trials 3: Mitral

10:30 AM — 11:30 AM EDT

Two-Year Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study

Gilbert H. L. Tang

Clinical and Quality-of-Life Outcomes With the PASCAL System in Early Commercial Experience From the STS/ACC TVT Registry

Santiago Garcia

Global and Regional Burden of Non-Rheumatic Degenerative Mitral Valve Disease: Implications for Transcatheter Therapies

Guido Ascione

One Year Results of a Clinical Study Using a Novel Polymeric Valve for Surgical Mitral Valve Replacement

Isaac George

A world-class educational experience, New York Valves features three days of transformative research and techniques that redefine the landscape of structural heart interventions. This dynamic meeting brings together interventional cardiologists, cardiac surgeons, clinical cardiologists, cardiac imagers, heart failure specialists, and other members of the heart team in the spirit of multidisciplinary collaboration. Attendees will have the unique opportunity to leverage the collective expertise of diverse specialties to create innovative and personalized treatment strategies for patients with valvular and structural heart disease.

In addition to the 12 late-breaking trials, New York Valves will feature:

HOW TO REGISTER:

Media may apply for press registration by emailing jromero@crf.org.

About CRF® 

The Cardiovascular Research Foundation® (CRF®) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF® not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF®’s centers of excellence include the CRF® Skirball Center for Innovation, CRF® Clinical Trials Center, CRF® Center for Education, CRF® Digital, TCTMD®, and Structural Heart: The Journal of the Heart Team

###

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.